Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Factor VIII"" wg kryterium: Temat


Tytuł :
A Novel, Enriched Population Pharmacokinetic Model for Recombinant Factor VIII-Fc Fusion Protein Concentrate in Hemophilia A Patients.
Autorzy :
Bukkems LH; Hospital Pharmacy-Clinical Pharmacology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Heijdra JM; Department of Pediatric Hematology, Erasmus University Medical Center - Sophia Children's Hospital Rotterdam, Rotterdam, The Netherlands.
Mathias M; Haemophilia Comprehensive Care Centre, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom.
Collins PW; Arthur Bloom Haemophilia Centre, School of Medicine, Cardiff University Hospital, Cardiff, United Kingdom.
Hay CRM; University Department of Haematology, Manchester University NHS Foundation Trust, Manchester, United Kingdom.
Tait RC; Department of Haematology, Royal Infirmary, Glasgow, United Kingdom.
Mangles S; Haemophilia, Haemostasis and Thrombosis Centre, Hampshire Hospitals NHS Foundation Trust, Basingstoke, United Kingdom.
Myers B; Department of Haematology, United Lincolnshire Hospitals NHS Trust, Lincoln, United Kingdom.
Evans G; Department of Haematology, East Kent Hospitals University NHS Foundation Trust, Kent, United Kingdom.
Bailiff B; Department Haematology and Blood Transfusion, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom.
Curry N; Oxford Haemophilia and Thrombosis Centre and Oxford NIHR BRC, Churchill Hospital, Oxford, United Kingdom.
Payne J; Department of PaediatricHaematology, Sheffield Children's NHS Foundation Trust, Sheffield, United Kingdom.
Austin S; Centre for Haemostasis and Thrombosis, St George's University Hospitals NHS Foundation Trust, London, United Kingdom.
Goedhart TMHJ; Department of Pediatric Hematology, Erasmus University Medical Center - Sophia Children's Hospital Rotterdam, Rotterdam, The Netherlands.
Leebeek FWG; Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Meijer K; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Fijnvandraat K; Department of Pediatrics, Amsterdam University Medical Centers, The Netherlands.
Chowdary P; Katharine DormandyHaemophilia Centre and Thrombosis Unit, Royal Free London NHS Foundation Trust, London, United Kingdom.
Mathôt RAA; Hospital Pharmacy-Clinical Pharmacology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Cnossen MH; Department of Pediatric Hematology, Erasmus University Medical Center - Sophia Children's Hospital Rotterdam, Rotterdam, The Netherlands.
Pokaż więcej
Corporate Authors :
for UK-EHL Outcomes Registry OPTI-CLOT Collaboration
Źródło :
Thrombosis and haemostasis [Thromb Haemost] 2020 May; Vol. 120 (5), pp. 747-757. Date of Electronic Publication: 2020 May 05.
Typ publikacji :
Case Reports; Journal Article; Multicenter Study; Validation Study
Journal Info :
Publisher: Thieme Country of Publication: Germany NLM ID: 7608063 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2567-689X (Electronic) Linking ISSN: 03406245 NLM ISO Abbreviation: Thromb. Haemost. Subsets: MEDLINE
MeSH Terms :
Models, Biological*
Factor VIII/*pharmacokinetics
Hemophilia A/*drug therapy
Hemostatics/*pharmacokinetics
Recombinant Fusion Proteins/*pharmacokinetics
Adolescent ; Adult ; Age Factors ; Aged ; Child ; Factor VIII/administration & dosage ; Factor VIII/adverse effects ; Hemophilia A/blood ; Hemophilia A/diagnosis ; Hemostatics/administration & dosage ; Hemostatics/adverse effects ; Humans ; Immunoglobulin Fc Fragments/administration & dosage ; Immunoglobulin Fc Fragments/adverse effects ; Male ; Middle Aged ; Netherlands ; Recombinant Fusion Proteins/administration & dosage ; Recombinant Fusion Proteins/adverse effects ; Registries ; Reproducibility of Results ; United Kingdom ; Young Adult
Czasopismo naukowe
Tytuł :
Overshoot of FVIII activity in patients with acquired hemophilia A who achieve complete remission.
Autorzy :
Ogawa Y; Department of Hematology, Gunma University Graduate School of Medicine, Maebashi, Japan. .; The Japanese Collaborative Research Group (JCRG) on Acquired Coagulopathies Supported by the Japanese Ministry of Health, Labour and Welfare, Yamagata, Japan. .
Yanagisawa K; Department of Hematology, Gunma University Graduate School of Medicine, Maebashi, Japan.
Naito C; Department of Hematology, Gunma University Graduate School of Medicine, Maebashi, Japan.
Uchiumi H; Department of Hematology, Gunma University Graduate School of Medicine, Maebashi, Japan.; Hidaka-Kai Shirane Clinic, Numata, Japan.
Ishizaki T; Department of Hematology, Gunma University Graduate School of Medicine, Maebashi, Japan.
Shimizu H; Department of Hematology, Gunma University Graduate School of Medicine, Maebashi, Japan.
Gohda F; Department of Internal Medicine, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.
Ieko M; The Japanese Collaborative Research Group (JCRG) on Acquired Coagulopathies Supported by the Japanese Ministry of Health, Labour and Welfare, Yamagata, Japan.; Department of Internal Medicine, School of Dentistry, Health Sciences University of Hokkaido, Ishikari-Tonetsu, Japan.
Ichinose A; The Japanese Collaborative Research Group (JCRG) on Acquired Coagulopathies Supported by the Japanese Ministry of Health, Labour and Welfare, Yamagata, Japan.; Department of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata, Japan.
Handa H; Department of Hematology, Gunma University Graduate School of Medicine, Maebashi, Japan.
Pokaż więcej
Źródło :
International journal of hematology [Int J Hematol] 2020 Apr; Vol. 111 (4), pp. 544-549. Date of Electronic Publication: 2020 Jan 14.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Springer Japan Country of Publication: Japan NLM ID: 9111627 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-3774 (Electronic) Linking ISSN: 09255710 NLM ISO Abbreviation: Int. J. Hematol. Subsets: MEDLINE
MeSH Terms :
Factor VIII/*immunology
Hemophilia A/*drug therapy
Hemophilia A/*immunology
Immunosuppressive Agents/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Autoantibodies ; Factor VIII/metabolism ; Female ; Humans ; Male ; Middle Aged ; Rare Diseases ; Remission Induction ; Retrospective Studies ; Treatment Outcome ; Venous Thromboembolism/etiology
SCR Disease Name :
Factor 8 deficiency, acquired
Czasopismo naukowe
Tytuł :
Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis.
Autorzy :
Chowdary P; Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free London NHS Foundation Trust, London, United Kingdom.
Fischer K; Van Creveldkliniek, Department of Hematology, University Medical Center, Utrecht, The Netherlands.
Collins PW; School of Medicine, Cardiff University, Cardiff, United Kingdom.
Cotterill A; Baxalta Innovations GmbH, a member of the Takeda group of companies, Vienna, Austria.
Konkle BA; Bloodworks Northwest, Seattle, Washington, United States.; Department of Medicine, University of Washington, Seattle, Washington, United States.
Blanchette V; Department of Paediatrics, Division of Haematology/Oncology, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Pipe SW; Department of Pediatrics and Pathology, University of Michigan, Ann Arbor, Michigan, United States.
Berntorp E; Department of Translational Medicine and Centre for Thrombosis and Haemostasis, Lund University, Malmö, Sweden.
Wolfsegger M; Baxalta Innovations GmbH, a member of the Takeda group of companies, Vienna, Austria.
Engl W; Baxalta Innovations GmbH, a member of the Takeda group of companies, Vienna, Austria.
Spotts G; Baxalta US Inc, a member of the Takeda group of companies, Lexington, Massachusetts, United States.
Pokaż więcej
Źródło :
Thrombosis and haemostasis [Thromb Haemost] 2020 May; Vol. 120 (5), pp. 728-736. Date of Electronic Publication: 2020 May 05.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial
Journal Info :
Publisher: Thieme Country of Publication: Germany NLM ID: 7608063 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2567-689X (Electronic) Linking ISSN: 03406245 NLM ISO Abbreviation: Thromb. Haemost. Subsets: MEDLINE
MeSH Terms :
Models, Biological*
Tertiary Prevention*
Factor VIII/*pharmacokinetics
Hemarthrosis/*prevention & control
Hemophilia A/*drug therapy
Hemostasis/*drug effects
Hemostatics/*pharmacokinetics
Adolescent ; Adult ; Canada ; Child ; Europe ; Factor VIII/administration & dosage ; Hemarthrosis/blood ; Hemarthrosis/diagnosis ; Hemophilia A/blood ; Hemophilia A/diagnosis ; Hemostatics/administration & dosage ; Hemostatics/blood ; Humans ; Middle Aged ; Risk Factors ; Severity of Illness Index ; United States ; Young Adult
Czasopismo naukowe
Tytuł :
A Closed-Tube Nested Quantitative PCR Assay for Rapid Detection of Intron 22 Inversions in the Factor VIII Gene.
Autorzy :
Jin S; School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang, China.; Key Laboratory of Laboratory Medicine, Ministry of Education, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Shang Q; School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang, China.; Key Laboratory of Laboratory Medicine, Ministry of Education, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Jin W; School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang, China.; Key Laboratory of Laboratory Medicine, Ministry of Education, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yang L; School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang, China.; Key Laboratory of Laboratory Medicine, Ministry of Education, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Ye Q; School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang, China.; Key Laboratory of Laboratory Medicine, Ministry of Education, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Wang X; School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang, China.; Key Laboratory of Laboratory Medicine, Ministry of Education, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Zhang T; School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang, China.; Key Laboratory of Laboratory Medicine, Ministry of Education, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Hou M; School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang, China.; Key Laboratory of Laboratory Medicine, Ministry of Education, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Liu Y; School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang, China.; Key Laboratory of Laboratory Medicine, Ministry of Education, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Han J; School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang, China.; Key Laboratory of Laboratory Medicine, Ministry of Education, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Ding R; School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang, China.; Key Laboratory of Laboratory Medicine, Ministry of Education, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Luan J; School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang, China.; Key Laboratory of Laboratory Medicine, Ministry of Education, Wenzhou Medical University, Wenzhou, Zhejiang, China.; Innovation Biomedical Co., Ltd., Wenzhou, Zhejiang, China.
Wang X; Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.; Faculty of Laboratory Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jiang M; Department of Laboratory Medicine, The Second Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Ding C; School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang, China.; Key Laboratory of Laboratory Medicine, Ministry of Education, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Pokaż więcej
Źródło :
Clinical chemistry [Clin Chem] 2020 Feb 01; Vol. 66 (2), pp. 373-378.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
Journal Info :
Publisher: Oxford University Press Country of Publication: England NLM ID: 9421549 Publication Model: Print Cited Medium: Internet ISSN: 1530-8561 (Electronic) Linking ISSN: 00099147 NLM ISO Abbreviation: Clin. Chem. Subsets: MEDLINE
MeSH Terms :
Factor VIII/*genetics
Hemophilia A/*diagnosis
Real-Time Polymerase Chain Reaction/*methods
Chromosome Inversion/genetics ; Factor VIII/analysis ; Factor VIII/metabolism ; Female ; Genotype ; Hemophilia A/genetics ; Humans ; Introns/genetics ; Male ; Sequence Inversion/genetics
Czasopismo naukowe
Tytuł :
Switching toward the use of recombinant factor VIII Fc fusion protein Study among 30 patients with severe hemophilia A.
Transliterated Title :
Switch vers un facteur VIII recombinant fusionné avec un fragment Fc Expérience chez 30 patients hémophiles A.
Autorzy :
Sattler L; Laboratoire d'hématologie, CHU Hautepierre, Strasbourg, France.
Raissi A; Laboratoire d'hématologie, CHR Mulhouse, Mulhouse, France.
Fornoff D; Laboratoire d'hématologie, CHU Hautepierre, Strasbourg, France.
Gérout AC; Service de pharmacie, CHU Hautepierre, Strasbourg, France.
Feugeas O; Centre de ressource et de compétence, maladie hémorragique constitutionnelle, CHU Hautepierre, Strasbourg, France.
Grunebaum L; Laboratoire d'hématologie, CHU Hautepierre, Strasbourg, France.
Desprez D; Centre de ressource et de compétence, maladie hémorragique constitutionnelle, CHU Hautepierre, Strasbourg, France.
Pokaż więcej
Źródło :
Annales de biologie clinique [Ann Biol Clin (Paris)] 2020 Feb 01; Vol. 78 (1), pp. 35-46.
Typ publikacji :
Clinical Trial; Journal Article
Journal Info :
Publisher: John Libbey Eurotext Country of Publication: France NLM ID: 2984690R Publication Model: Print Cited Medium: Internet ISSN: 1950-6112 (Electronic) Linking ISSN: 00033898 NLM ISO Abbreviation: Ann. Biol. Clin. (Paris) Subsets: MEDLINE
MeSH Terms :
Drug Substitution*
Factor VIII/*therapeutic use
Hemophilia A/*drug therapy
Immunoglobulin Fc Fragments/*therapeutic use
Recombinant Fusion Proteins/*therapeutic use
Adolescent ; Adult ; Aged ; Blood Coagulation Tests ; Factor VIII/analysis ; Factor VIII/pharmacokinetics ; Half-Life ; Hemophilia A/blood ; Hemophilia A/metabolism ; Hemophilia A/pathology ; Humans ; Male ; Middle Aged ; Patient Satisfaction ; Recombinant Fusion Proteins/pharmacokinetics ; Severity of Illness Index ; Thrombin/metabolism ; Young Adult
Czasopismo naukowe
Tytuł :
Physiological Roles of the von Willebrand Factor-Factor VIII Interaction.
Autorzy :
Kiouptsi K; Center for Thrombosis and Hemostasis (CTH), University Medical Center Mainz, Langenbeckstrasse 1, Building 708, 55131, Mainz, Germany.
Reinhardt C; Center for Thrombosis and Hemostasis (CTH), University Medical Center Mainz, Langenbeckstrasse 1, Building 708, 55131, Mainz, Germany. .; German Center for Cardiovascular Research (DZHK), Partner Site RheinMain, Mainz, Germany. .
Pokaż więcej
Źródło :
Sub-cellular biochemistry [Subcell Biochem] 2020; Vol. 94, pp. 437-464.
Typ publikacji :
Journal Article; Review
Journal Info :
Publisher: Springer Country of Publication: United States NLM ID: 0316571 Publication Model: Print Cited Medium: Print ISSN: 0306-0225 (Print) Linking ISSN: 03060225 NLM ISO Abbreviation: Subcell. Biochem. Subsets: MEDLINE
MeSH Terms :
Cardiovascular Physiological Phenomena*
Factor VIII/*metabolism
von Willebrand Factor/*metabolism
Factor VIII/chemistry ; Hemophilia A/metabolism ; Humans ; von Willebrand Diseases/metabolism ; von Willebrand Factor/chemistry
Czasopismo naukowe
Tytuł :
Hemophilia A in Females: Considerations for Clinical Management.
Autorzy :
Bryant P; St Jude Affiliate Clinic at Novant Health Hemby Children's Hospital, Charlotte, North Carolina, USA.
Boukouvala A; Arizona Bleeding Disorders Health and Wellness Center, Phoenix, Arizona, USA.
McDaniel J; St Jude Affiliate Clinic at Novant Health Hemby Children's Hospital, Charlotte, North Carolina, USA.
Nance D; Banner MD Anderson Cancer Center, Gilbert, Arizona, USA, .
Pokaż więcej
Źródło :
Acta haematologica [Acta Haematol] 2020; Vol. 143 (3), pp. 289-294. Date of Electronic Publication: 2019 Dec 11.
Typ publikacji :
Case Reports
Journal Info :
Publisher: Karger Country of Publication: Switzerland NLM ID: 0141053 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1421-9662 (Electronic) Linking ISSN: 00015792 NLM ISO Abbreviation: Acta Haematol. Subsets: MEDLINE
MeSH Terms :
Factor VIII/*genetics
Hemophilia A/*genetics
Adolescent ; Aged ; Chromosome Inversion ; Deamino Arginine Vasopressin/adverse effects ; Deamino Arginine Vasopressin/therapeutic use ; Disease Management ; Drug Substitution ; Factor VIII/analysis ; Factor VIII/therapeutic use ; Female ; Hemarthrosis/etiology ; Hemophilia A/complications ; Hemophilia A/diagnosis ; Hemophilia A/drug therapy ; Heterozygote ; Humans ; Introns/genetics ; Male ; Menorrhagia/etiology ; Middle Aged ; Pedigree ; Recombinant Proteins/therapeutic use ; Tranexamic Acid/therapeutic use ; Young Adult
Raport
Tytuł :
Fibrinogen Concentrate as an Alternative to Cryoprecipitate in a Postcardiopulmonary Transfusion Algorithm in Infants Undergoing Cardiac Surgery: A Prospective Randomized Controlled Trial.
Autorzy :
Downey LA; From the Department of Anesthesiology, Perioperative and Pain Medicine, Emory University, Children's Healthcare of Atlanta, Atlanta, Georgia.
Andrews J; Departments of Pathology, Microbiology, and Immunology.; Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.
Hedlin H; Department of Quantitative Sciences Unit, Stanford University School of Medicine, Palo Alto, California.
Kamra K; Department of Anesthesiology, Stanford University School of Medicine, Lucile Packard Children's Hospital, Palo Alto, California.
McKenzie ED; Division of Congenital Heart Surgery, Department of Surgery, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas.
Hanley FL; Departments of Cardiovascular Surgery.; Pediatric Cardiac Surgery, Stanford University School of Medicine, Lucile Packard Children's Hospital, Palo Alto, California.
Williams GD; Department of Anesthesiology, Stanford University School of Medicine, Lucile Packard Children's Hospital, Palo Alto, California.
Guzzetta NA; From the Department of Anesthesiology, Perioperative and Pain Medicine, Emory University, Children's Healthcare of Atlanta, Atlanta, Georgia.
Pokaż więcej
Źródło :
Anesthesia and analgesia [Anesth Analg] 2020 Mar; Vol. 130 (3), pp. 740-751.
Typ publikacji :
Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
Journal Info :
Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 1310650 Publication Model: Print Cited Medium: Internet ISSN: 1526-7598 (Electronic) Linking ISSN: 00032999 NLM ISO Abbreviation: Anesth. Analg. Subsets: Core Clinical (AIM); MEDLINE
MeSH Terms :
Algorithms*
Blood Transfusion*
Clinical Protocols*
Afibrinogenemia/*drug therapy
Blood Loss, Surgical/*prevention & control
Cardiac Surgical Procedures/*adverse effects
Coagulants/*administration & dosage
Factor VIII/*administration & dosage
Fibrinogen/*administration & dosage
Postoperative Hemorrhage/*therapy
Afibrinogenemia/blood ; Afibrinogenemia/etiology ; Age Factors ; Blood Coagulation/drug effects ; Coagulants/adverse effects ; Factor VIII/adverse effects ; Female ; Fibrinogen/adverse effects ; Humans ; Infant ; Male ; Postoperative Hemorrhage/blood ; Postoperative Hemorrhage/etiology ; Prospective Studies ; Risk Factors ; Time Factors ; Treatment Outcome ; United States
Czasopismo naukowe
Tytuł :
Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A.
Autorzy :
Pasi KJ; From Barts and the London School of Medicine and Dentistry (K.J.P.), Guy's and St. Thomas' NHS Foundation Trust (B.M.), and the Centre for Haematology, Imperial College London (M. Laffan), London, University Hospital Southampton, Southampton (S.R.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (W.L.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (E.S.) - all in the United Kingdom; and BioMarin Pharmaceutical, Novato (N.M., C.B.R., M. Li, W.Y.W.), and private consultant, La Jolla (G.F.P.) - both in California.
Rangarajan S; From Barts and the London School of Medicine and Dentistry (K.J.P.), Guy's and St. Thomas' NHS Foundation Trust (B.M.), and the Centre for Haematology, Imperial College London (M. Laffan), London, University Hospital Southampton, Southampton (S.R.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (W.L.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (E.S.) - all in the United Kingdom; and BioMarin Pharmaceutical, Novato (N.M., C.B.R., M. Li, W.Y.W.), and private consultant, La Jolla (G.F.P.) - both in California.
Mitchell N; From Barts and the London School of Medicine and Dentistry (K.J.P.), Guy's and St. Thomas' NHS Foundation Trust (B.M.), and the Centre for Haematology, Imperial College London (M. Laffan), London, University Hospital Southampton, Southampton (S.R.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (W.L.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (E.S.) - all in the United Kingdom; and BioMarin Pharmaceutical, Novato (N.M., C.B.R., M. Li, W.Y.W.), and private consultant, La Jolla (G.F.P.) - both in California.
Lester W; From Barts and the London School of Medicine and Dentistry (K.J.P.), Guy's and St. Thomas' NHS Foundation Trust (B.M.), and the Centre for Haematology, Imperial College London (M. Laffan), London, University Hospital Southampton, Southampton (S.R.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (W.L.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (E.S.) - all in the United Kingdom; and BioMarin Pharmaceutical, Novato (N.M., C.B.R., M. Li, W.Y.W.), and private consultant, La Jolla (G.F.P.) - both in California.
Symington E; From Barts and the London School of Medicine and Dentistry (K.J.P.), Guy's and St. Thomas' NHS Foundation Trust (B.M.), and the Centre for Haematology, Imperial College London (M. Laffan), London, University Hospital Southampton, Southampton (S.R.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (W.L.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (E.S.) - all in the United Kingdom; and BioMarin Pharmaceutical, Novato (N.M., C.B.R., M. Li, W.Y.W.), and private consultant, La Jolla (G.F.P.) - both in California.
Madan B; From Barts and the London School of Medicine and Dentistry (K.J.P.), Guy's and St. Thomas' NHS Foundation Trust (B.M.), and the Centre for Haematology, Imperial College London (M. Laffan), London, University Hospital Southampton, Southampton (S.R.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (W.L.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (E.S.) - all in the United Kingdom; and BioMarin Pharmaceutical, Novato (N.M., C.B.R., M. Li, W.Y.W.), and private consultant, La Jolla (G.F.P.) - both in California.
Laffan M; From Barts and the London School of Medicine and Dentistry (K.J.P.), Guy's and St. Thomas' NHS Foundation Trust (B.M.), and the Centre for Haematology, Imperial College London (M. Laffan), London, University Hospital Southampton, Southampton (S.R.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (W.L.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (E.S.) - all in the United Kingdom; and BioMarin Pharmaceutical, Novato (N.M., C.B.R., M. Li, W.Y.W.), and private consultant, La Jolla (G.F.P.) - both in California.
Russell CB; From Barts and the London School of Medicine and Dentistry (K.J.P.), Guy's and St. Thomas' NHS Foundation Trust (B.M.), and the Centre for Haematology, Imperial College London (M. Laffan), London, University Hospital Southampton, Southampton (S.R.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (W.L.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (E.S.) - all in the United Kingdom; and BioMarin Pharmaceutical, Novato (N.M., C.B.R., M. Li, W.Y.W.), and private consultant, La Jolla (G.F.P.) - both in California.
Li M; From Barts and the London School of Medicine and Dentistry (K.J.P.), Guy's and St. Thomas' NHS Foundation Trust (B.M.), and the Centre for Haematology, Imperial College London (M. Laffan), London, University Hospital Southampton, Southampton (S.R.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (W.L.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (E.S.) - all in the United Kingdom; and BioMarin Pharmaceutical, Novato (N.M., C.B.R., M. Li, W.Y.W.), and private consultant, La Jolla (G.F.P.) - both in California.
Pierce GF; From Barts and the London School of Medicine and Dentistry (K.J.P.), Guy's and St. Thomas' NHS Foundation Trust (B.M.), and the Centre for Haematology, Imperial College London (M. Laffan), London, University Hospital Southampton, Southampton (S.R.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (W.L.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (E.S.) - all in the United Kingdom; and BioMarin Pharmaceutical, Novato (N.M., C.B.R., M. Li, W.Y.W.), and private consultant, La Jolla (G.F.P.) - both in California.
Wong WY; From Barts and the London School of Medicine and Dentistry (K.J.P.), Guy's and St. Thomas' NHS Foundation Trust (B.M.), and the Centre for Haematology, Imperial College London (M. Laffan), London, University Hospital Southampton, Southampton (S.R.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (W.L.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (E.S.) - all in the United Kingdom; and BioMarin Pharmaceutical, Novato (N.M., C.B.R., M. Li, W.Y.W.), and private consultant, La Jolla (G.F.P.) - both in California.
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2020 Jan 02; Vol. 382 (1), pp. 29-40.
Typ publikacji :
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
Journal Info :
Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N. Engl. J. Med. Subsets: Core Clinical (AIM); MEDLINE
MeSH Terms :
Dependovirus*
Genetic Therapy*/adverse effects
Genetic Vectors*
Factor VIII/*genetics
Hemophilia A/*therapy
Adult ; Biomarkers ; Coagulants/therapeutic use ; Factor VIII/therapeutic use ; Follow-Up Studies ; Hemophilia A/complications ; Hemorrhage/etiology ; Hemorrhage/prevention & control ; Humans ; Infusions, Intravenous ; Male ; Middle Aged ; Transgenes ; Young Adult
Czasopismo naukowe
Tytuł :
Advances in gene therapy for hemophilia: basis, current status, and future perspectives.
Autorzy :
Ohmori T; Department of Biochemistry, Jichi Medical University School of Medicine, 3111-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan. .
Pokaż więcej
Źródło :
International journal of hematology [Int J Hematol] 2020 Jan; Vol. 111 (1), pp. 31-41. Date of Electronic Publication: 2018 Aug 06.
Typ publikacji :
Journal Article; Review
Journal Info :
Publisher: Springer Japan Country of Publication: Japan NLM ID: 9111627 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-3774 (Electronic) Linking ISSN: 09255710 NLM ISO Abbreviation: Int. J. Hematol. Subsets: MEDLINE
MeSH Terms :
Dependovirus/*genetics
Factor IX/*genetics
Factor VIII/*genetics
Genetic Therapy/*methods
Hemophilia A/*genetics
Hemophilia A/*therapy
Animals ; CD8-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/metabolism ; Child ; Dependovirus/immunology ; Factor VIII/metabolism ; Gene Editing/methods ; Gene Expression ; Genetic Vectors/immunology ; Genetic Vectors/therapeutic use ; Hemophilia B/genetics ; Hemophilia B/metabolism ; Hemophilia B/therapy ; Hemorrhage/blood ; Hemorrhage/genetics ; Humans
Czasopismo naukowe
Tytuł :
Investigating the influence of LCT rs3754689 polymorphism on inhibitor development in Iranian and Afghan patients with severe hemophilia A.
Autorzy :
Bahrami Zadegan S; Department of Biotechnology, College of Science, University of Tehran.; Dr Zeinali's Medical Genetics Laboratory, Kawsar Human Genetics Research Center, Tehran, Iran.
Mousavi SH; Medical Research Center, Kateb University.; Afghanistan National Charity Organization for Special Diseases (ANCOSD), Kabul, Afghanistan.
Damavandi N; Department of Biotechnology, College of Science, University of Tehran.; Dr Zeinali's Medical Genetics Laboratory, Kawsar Human Genetics Research Center, Tehran, Iran.
Samiee Aref MH; Department of Biotechnology, College of Science, University of Tehran.; Dr Zeinali's Medical Genetics Laboratory, Kawsar Human Genetics Research Center, Tehran, Iran.
Zeinali S; Department of Biotechnology, College of Science, University of Tehran.; Dr Zeinali's Medical Genetics Laboratory, Kawsar Human Genetics Research Center, Tehran, Iran.; Department of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Pokaż więcej
Źródło :
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis [Blood Coagul Fibrinolysis] 2020 Jan; Vol. 31 (1), pp. 11-15.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Lippincott Williams And Wilkins Country of Publication: England NLM ID: 9102551 Publication Model: Print Cited Medium: Internet ISSN: 1473-5733 (Electronic) Linking ISSN: 09575235 NLM ISO Abbreviation: Blood Coagul. Fibrinolysis Subsets: MEDLINE
MeSH Terms :
Factor VIII/*therapeutic use
Hemophilia A/*drug therapy
Hemophilia A/*epidemiology
Polymorphism, Genetic/*genetics
Factor VIII/pharmacology ; Genotype ; Humans ; Iran ; Mutation
Czasopismo naukowe
Tytuł :
Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
Autorzy :
Patel AM; Genentech, Inc, San Francisco, CA, USA.
Corman SL; Pharmerit International, Bethesda, MD, USA.
Chaplin S; Pharmerit International, Bethesda, MD, USA.
Raimundo K; Genentech, Inc, San Francisco, CA, USA.
Sidonio RF; Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA, USA.
Pokaż więcej
Źródło :
Journal of medical economics [J Med Econ] 2019 Dec; Vol. 22 (12), pp. 1328-1337. Date of Electronic Publication: 2019 Oct 07.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Taylor & Francis Country of Publication: England NLM ID: 9892255 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1941-837X (Electronic) Linking ISSN: 13696998 NLM ISO Abbreviation: J Med Econ Subsets: MEDLINE
MeSH Terms :
Antibodies, Bispecific/*therapeutic use
Antibodies, Monoclonal, Humanized/*therapeutic use
Coagulants/*therapeutic use
Factor VIII/*therapeutic use
Hemophilia A/*drug therapy
Hemorrhage/*prevention & control
Antibodies, Bispecific/economics ; Antibodies, Bispecific/immunology ; Antibodies, Monoclonal, Humanized/economics ; Antibodies, Monoclonal, Humanized/immunology ; Coagulants/administration & dosage ; Coagulants/immunology ; Factor VIII/administration & dosage ; Factor VIII/immunology ; Humans ; Models, Economic ; Severity of Illness Index
Czasopismo naukowe
Tytuł :
Mechanisms of vascular permeability and remodeling associated with hemarthrosis in factor VIII-deficient mice.
Autorzy :
Cooke EJ; Division of Hematology/Oncology, Department of Medicine, University of California San Diego, La Jolla, CA.; Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA.
Wyseure T; Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA.
Zhou JY; Division of Hematology/Oncology, Department of Medicine, University of California San Diego, La Jolla, CA.
Gopal S; Division of Hematology/Oncology, Department of Medicine, University of California San Diego, La Jolla, CA.
Nasamran CA; Center for Computational Biology and Bioinformatics, University of California San Diego, La Jolla, CA.
Fisch KM; Center for Computational Biology and Bioinformatics, University of California San Diego, La Jolla, CA.
Manon-Jensen T; Nordic Bioscience, Biomarker and Research, Herlev, Denmark.
Karsdal MA; Nordic Bioscience, Biomarker and Research, Herlev, Denmark.
Mosnier LO; Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA.
von Drygalski A; Division of Hematology/Oncology, Department of Medicine, University of California San Diego, La Jolla, CA.; Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA.
Pokaż więcej
Źródło :
Journal of thrombosis and haemostasis : JTH [J Thromb Haemost] 2019 Nov; Vol. 17 (11), pp. 1815-1826. Date of Electronic Publication: 2019 Aug 09.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info :
Publisher: Blackwell Pub Country of Publication: England NLM ID: 101170508 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-7836 (Electronic) Linking ISSN: 15387836 NLM ISO Abbreviation: J. Thromb. Haemost. Subsets: MEDLINE
MeSH Terms :
Capillary Permeability*/drug effects
Vascular Remodeling*/drug effects
Factor VIII/*metabolism
Hemarthrosis/*metabolism
Hemophilia A/*metabolism
Synovial Membrane/*blood supply
Animals ; Disease Models, Animal ; Factor VIII/administration & dosage ; Factor VIII/genetics ; Female ; Hemarthrosis/genetics ; Hemarthrosis/physiopathology ; Hemarthrosis/prevention & control ; Hemophilia A/drug therapy ; Hemophilia A/genetics ; Hemophilia A/physiopathology ; Hemostasis ; Hemostatics/administration & dosage ; Male ; Mice, Inbred BALB C ; Mice, Knockout ; Time Factors
Czasopismo naukowe
Tytuł :
Hemophilia A with inhibitor: Immune tolerance induction (ITI) in the mirror of time.
Autorzy :
Nakar C; The Indiana Hemophilia and Thrombosis Center (IHTC), Indianapolis, IN, USA. Electronic address: .
Shapiro A; The Indiana Hemophilia and Thrombosis Center (IHTC), Indianapolis, IN, USA.
Pokaż więcej
Źródło :
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis [Transfus Apher Sci] 2019 Oct; Vol. 58 (5), pp. 578-589. Date of Electronic Publication: 2019 Aug 06.
Typ publikacji :
Journal Article; Review
Journal Info :
Publisher: Pergamon Country of Publication: England NLM ID: 101095653 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-0502 (Print) Linking ISSN: 14730502 NLM ISO Abbreviation: Transfus. Apher. Sci. Subsets: Health Technology
MeSH Terms :
Blood Coagulation Factor Inhibitors*/blood
Blood Coagulation Factor Inhibitors*/immunology
Factor VIII*/immunology
Factor VIII*/metabolism
Hemophilia A*/blood
Hemophilia A*/immunology
Hemophilia A*/therapy
Immune Tolerance*
Immunosuppression*
Antibodies, Bispecific/*therapeutic use
Antibodies, Monoclonal, Humanized/*therapeutic use
Hemorrhage/blood ; Hemorrhage/therapy ; Humans
Czasopismo naukowe
Tytuł :
The Effect of Fluctuating Temperature on the Stability of Turoctocog Alfa for Hemophilia A.
Autorzy :
Napolitano M; Reference Regional Center for Thrombosis and Hemostasis, Haematology Unit, University Hospital Policlinico 'Paolo Giaccone', University of Palermo, Via del Vespro 129, 90127, Palermo, Italy. .
Nøhr AM; Novo Nordisk A/S, Biopharm Project Offices, Bagsværd, Denmark.
Pokaż więcej
Źródło :
Drugs in R&D [Drugs R D] 2019 Dec; Vol. 19 (4), pp. 381-390.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 100883647 Publication Model: Print Cited Medium: Internet ISSN: 1179-6901 (Electronic) Linking ISSN: 11745886 NLM ISO Abbreviation: Drugs R D Subsets: MEDLINE
MeSH Terms :
Factor VIII/*chemistry
Factor VIII/*standards
Hemophilia A/*drug therapy
Recombinant Proteins/*chemistry
Recombinant Proteins/*standards
Cold Temperature ; Drug Stability ; Drug Storage ; Factor VIII/therapeutic use ; Hot Temperature ; Humans ; Molecular Weight ; Oxidation-Reduction ; Recombinant Proteins/therapeutic use ; Time Factors
Czasopismo naukowe
Tytuł :
Mixing-based inhibitor screening in haemophilia A: challenges in interpretation.
Autorzy :
Arshad S; Department of Pathology, Dr Ram Manohar Lohia Institute of Medical Sciences, Lucknow, India.
Awasthi NP
Husain N
Neyaz A
Singh A
Pokaż więcej
Źródło :
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis [Blood Coagul Fibrinolysis] 2019 Dec; Vol. 30 (8), pp. 401-408.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Lippincott Williams And Wilkins Country of Publication: England NLM ID: 9102551 Publication Model: Print Cited Medium: Internet ISSN: 1473-5733 (Electronic) Linking ISSN: 09575235 NLM ISO Abbreviation: Blood Coagul. Fibrinolysis Subsets: MEDLINE
MeSH Terms :
Blood Coagulation Factor Inhibitors/*analysis
Factor VIII/*therapeutic use
Hemophilia A/*complications
Antibodies/blood ; Blood Coagulation Factor Inhibitors/blood ; Factor VIII/antagonists & inhibitors ; Factor VIII/immunology ; Hemophilia A/drug therapy ; Hemophilia A/immunology ; Humans ; Mass Screening/methods ; ROC Curve
Czasopismo naukowe
Tytuł :
[Successful treatment of acquired hemophilia A with recombinant porcine factor VIII].
Transliterated Title :
Erfolgreiche Behandlung einer erworbenen Hemmkörperhämophilie A mit rekombinantem porcinem Faktor VIII.
Autorzy :
Trautmann-Grill K; Medizinische Klinik I, Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Deutschland. .
Tiebel O; Institut für Klinische Chemie und Laboratoriumsmedizin, Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Deutschland.
Hölig K; Medizinische Klinik I, Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Deutschland.
Platzbecker U; Medizinische Klinik I, Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Deutschland.
Pokaż więcej
Źródło :
Medizinische Klinik, Intensivmedizin und Notfallmedizin [Med Klin Intensivmed Notfmed] 2019 Nov; Vol. 114 (8), pp. 746-748. Date of Electronic Publication: 2018 May 17.
Typ publikacji :
Case Reports; Journal Article
Journal Info :
Publisher: Springer Medizin Country of Publication: Germany NLM ID: 101575086 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2193-6226 (Electronic) Linking ISSN: 21936218 NLM ISO Abbreviation: Med Klin Intensivmed Notfmed Subsets: MEDLINE
MeSH Terms :
Autoantibodies*/blood
Autoantibodies*/immunology
Factor VIII*/immunology
Hemophilia A*/blood
Hemophilia A*/immunology
Aged ; Animals ; Blood Coagulation Tests ; Hemorrhage ; Humans ; Male ; Swine
Czasopismo naukowe
Tytuł :
Individual combinations of danger signals synergistically increase FVIII product immunogenicity.
Autorzy :
Miller L; Division of Immunology, Paul-Ehrlich-Institut, Langen, Germany.
Klemm J; Division of Immunology, Paul-Ehrlich-Institut, Langen, Germany.
Schmidt C; Division of Immunology, Paul-Ehrlich-Institut, Langen, Germany.
Hanschmann KM; Division of Microbiology, Paul-Ehrlich-Institut, Langen, Germany.
Bekeredjian-Ding I; Division of Microbiology, Paul-Ehrlich-Institut, Langen, Germany.
Waibler Z; Division of Immunology, Paul-Ehrlich-Institut, Langen, Germany.
Pokaż więcej
Źródło :
Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2019 Nov; Vol. 25 (6), pp. 996-1002. Date of Electronic Publication: 2019 Oct 04.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Blackwell Science Country of Publication: England NLM ID: 9442916 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2516 (Electronic) Linking ISSN: 13518216 NLM ISO Abbreviation: Haemophilia Subsets: MEDLINE
MeSH Terms :
Factor VIII/*immunology
Hemophilia A/*drug therapy
Hemophilia A/*immunology
Cell Differentiation/drug effects ; Cell Differentiation/immunology ; Dendritic Cells/cytology ; Dendritic Cells/drug effects ; Dendritic Cells/immunology ; Factor VIII/pharmacology ; Factor VIII/therapeutic use ; Humans ; Lipopolysaccharides/pharmacology ; Lymphocyte Activation/drug effects ; Lymphocyte Activation/immunology ; T-Lymphocytes/drug effects ; T-Lymphocytes/immunology
Czasopismo naukowe
Tytuł :
FVIII dosages in persons with haemophilia A treated with extended half-life products: From local biology to optimized patient management.
Autorzy :
Perrier-Cornet A; Service d'Hématologie Biologique, Centre Hospitalier Universitaire Bicêtre, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France.; Université Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
Philippe A; Service d'Hématologie Biologique, Centre Hospitalier Universitaire Bicêtre, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France.
Lambert T; Centre de Référence de l'Hémophilie et des Maladies Hémorragiques Constitutionnelles (CRH-MHC), Centre Hospitalier Universitaire Bicêtre, Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France.
d'Oiron R; Centre de Référence de l'Hémophilie et des Maladies Hémorragiques Constitutionnelles (CRH-MHC), Centre Hospitalier Universitaire Bicêtre, Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France.; INSERM, Unité Mixte de Recherche Scientifique 1176, Le Kremlin-Bicêtre France.
Rafowicz A; Centre de Référence de l'Hémophilie et des Maladies Hémorragiques Constitutionnelles (CRH-MHC), Centre Hospitalier Universitaire Bicêtre, Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France.
Lavenu-Bombled C; Service d'Hématologie Biologique, Centre Hospitalier Universitaire Bicêtre, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France.; Université Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France.; INSERM, Unité Mixte de Recherche Scientifique 1176, Le Kremlin-Bicêtre France.
Combe S; Service d'Hématologie Biologique, Centre Hospitalier Universitaire Bicêtre, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France.
Gillibert A; Biostatistics Department, Rouen University Hospital, Rouen, France.
Proulle V; Service d'Hématologie Biologique, Centre Hospitalier Universitaire Bicêtre, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France.; Université Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France.; INSERM, Unité Mixte de Recherche Scientifique 1176, Le Kremlin-Bicêtre France.
Pokaż więcej
Źródło :
Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2019 Nov; Vol. 25 (6), pp. e361-e363. Date of Electronic Publication: 2019 Jun 17.
Typ publikacji :
Letter
Journal Info :
Publisher: Blackwell Science Country of Publication: England NLM ID: 9442916 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2516 (Electronic) Linking ISSN: 13518216 NLM ISO Abbreviation: Haemophilia Subsets: MEDLINE
MeSH Terms :
Coagulants/*therapeutic use
Factor VIII/*therapeutic use
Hemophilia A/*drug therapy
Adolescent ; Adult ; Aged ; Child ; Child, Preschool ; Coagulants/administration & dosage ; Coagulants/pharmacokinetics ; Disease Management ; Drug Monitoring ; Factor VIII/administration & dosage ; Factor VIII/pharmacokinetics ; Half-Life ; Humans ; Middle Aged ; Recombinant Proteins/administration & dosage ; Recombinant Proteins/pharmacokinetics ; Recombinant Proteins/therapeutic use ; Young Adult
Opinia redakcyjna
Tytuł :
Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial.
Autorzy :
Santagostino E; Foundation IRCCS Ca' Granda, Maggiore Hospital Policlinico, Milan, Italy.
Lalezari S; Israel National Hemophilia Center, Chaim Sheba Medical Center, Tel Hashomer, Israel; Sackler School of Medicine, Tel-Aviv University, Israel.
Reding MT; Center for Bleeding and Clotting Disorders, University of Minnesota Medical Center, Minneapolis, MN, United States of America.
Ducore J; Hemophilia Treatment Center, UC Davis Medical Center, Sacramento, CA, United States of America.
Ng HJ; Department of Haematology, Singapore General Hospital, Singapore.
Poulsen LH; The Haemophilia Centre, Aarhus University Hospital, Aarhus, Denmark.
Michaels LA; Bayer, Whippany, NJ, United States of America.
Linardi CCG; Bayer, Whippany, NJ, United States of America. Electronic address: .
Pokaż więcej
Źródło :
Thrombosis research [Thromb Res] 2019 Nov; Vol. 183, pp. 13-19. Date of Electronic Publication: 2019 Aug 26.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Pergamon Press Country of Publication: United States NLM ID: 0326377 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-2472 (Electronic) Linking ISSN: 00493848 NLM ISO Abbreviation: Thromb. Res. Subsets: MEDLINE
MeSH Terms :
Coagulants/*therapeutic use
Factor VIII/*therapeutic use
Hemophilia A/*drug therapy
Polyethylene Glycols/*therapeutic use
Recombinant Proteins/*therapeutic use
Adolescent ; Adult ; Aged ; Child ; Coagulants/pharmacology ; Factor VIII/pharmacology ; Female ; Hemophilia A/pathology ; Humans ; Male ; Middle Aged ; Polyethylene Glycols/pharmacology ; Recombinant Proteins/pharmacology ; Treatment Outcome ; Young Adult
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies